Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.

2.50
Hdl Handle:
http://hdl.handle.net/10541/80243
Title:
Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.
Authors:
Kopchick, J J; Parkinson, Craig; Stevens, E C; Trainer, Peter J
Abstract:
An understanding of the events that occur during GH receptor (GHR) signaling has facilitated the development of a GHR antagonist (pegvisomant) for use in humans. This molecule has been designed to compete with native GH for the GHR and to prevent its proper or functional dimerization-a process that is critical for GH signal transduction and IGF-I synthesis and secretion. Clinical trials in patients with acromegaly show GHR blockade to be an exciting new mode of therapy for this condition, and pegvisomant may have a therapeutic role in diseases, such as diabetes and malignancy, in which abnormalities of the GH/IGF-I axis have been observed. This review charts the discovery and development of GHR antagonists and details the experience gained in patients with acromegaly.
Affiliation:
Edison Biotechnology Institute, Department of Biomedical Sciences, College of Osteopathic Medicine, Ohio University, Athens, Ohio 45701, USA.
Citation:
Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. 2002, 23 (5):623-46 Endocr. Rev.
Journal:
Endocrine Reviews
Issue Date:
Oct-2002
URI:
http://hdl.handle.net/10541/80243
PubMed ID:
12372843
Type:
Article
Language:
en
ISSN:
0163-769X
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorKopchick, J J-
dc.contributor.authorParkinson, Craig-
dc.contributor.authorStevens, E C-
dc.contributor.authorTrainer, Peter J-
dc.date.accessioned2009-09-08T10:37:04Z-
dc.date.available2009-09-08T10:37:04Z-
dc.date.issued2002-10-
dc.identifier.citationGrowth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. 2002, 23 (5):623-46 Endocr. Rev.en
dc.identifier.issn0163-769X-
dc.identifier.pmid12372843-
dc.identifier.urihttp://hdl.handle.net/10541/80243-
dc.description.abstractAn understanding of the events that occur during GH receptor (GHR) signaling has facilitated the development of a GHR antagonist (pegvisomant) for use in humans. This molecule has been designed to compete with native GH for the GHR and to prevent its proper or functional dimerization-a process that is critical for GH signal transduction and IGF-I synthesis and secretion. Clinical trials in patients with acromegaly show GHR blockade to be an exciting new mode of therapy for this condition, and pegvisomant may have a therapeutic role in diseases, such as diabetes and malignancy, in which abnormalities of the GH/IGF-I axis have been observed. This review charts the discovery and development of GHR antagonists and details the experience gained in patients with acromegaly.en
dc.language.isoenen
dc.subject.meshAcromegaly-
dc.subject.meshAnimals-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshDrug Design-
dc.subject.meshHuman Growth Hormone-
dc.subject.meshHumans-
dc.subject.meshModels, Molecular-
dc.subject.meshMolecular Structure-
dc.subject.meshReceptors, Somatotropin-
dc.subject.meshStructure-Activity Relationship-
dc.titleGrowth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.en
dc.typeArticleen
dc.contributor.departmentEdison Biotechnology Institute, Department of Biomedical Sciences, College of Osteopathic Medicine, Ohio University, Athens, Ohio 45701, USA.en
dc.identifier.journalEndocrine Reviewsen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.